Singular Genomics Systems (NASDAQ:OMIC) Receives New Coverage from Analysts at The Goldman Sachs Group

The Goldman Sachs Group assumed coverage on shares of Singular Genomics Systems (NASDAQ:OMIC) in a research report sent to investors on Monday morning, Price Targets.com reports. The firm issued a buy rating and a $35.00 target price on the stock.

Shares of Singular Genomics Systems stock opened at $23.16 on Monday. Singular Genomics Systems has a one year low of $22.90 and a one year high of $33.37.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

Read More: The limitations of an equal weight rating

Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.